



P R E S S R E L E A S E

Lelystad, 7 April 2011

SALE OF LAPROLAN TO ROCHESTER MEDICAL CORPORATION COMPLETED

Fornix BioSciences N.V. (**Fornix**) announces that the sale of Laprolan B.V. (**Laprolan**) as approved by the Extraordinary General Meeting of Shareholders of Fornix held on 30 March 2011 has been completed by the transfer of the entire issued share capital of Laprolan by Fornix to Rochester Medical Corporation on Thursday 7 April 2011 against payment of the agreed consideration payable.

E N D O F P R E S S R E L E A S E

For additional information, please contact: Fornix BioSciences N.V.
C.L. Bergman, CEO
Tel. +31 (0) 320) 26 77 99

Profile of Fornix BioSciences N.V.

Fornix BioSciences N.V. is a listed company (Euronext Amsterdam: AFORBI) which was engaged in the distribution of medical aids and medical and nursing consumables.

With the transfer of all of its shares in Laprolan B.V. to Rochester Medical Corporation, Fornix BioSciences N.V. has divested all of its activities.